260 related articles for article (PubMed ID: 30317611)
1. Overview of CD24 as a new molecular marker in ovarian cancer.
Tarhriz V; Bandehpour M; Dastmalchi S; Ouladsahebmadarek E; Zarredar H; Eyvazi S
J Cell Physiol; 2019 Mar; 234(3):2134-2142. PubMed ID: 30317611
[TBL] [Abstract][Full Text] [Related]
2. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients.
Soltész B; Lukács J; Szilágyi E; Márton É; Szilágyi Bónizs M; Penyige A; Póka R; Nagy B
J Biotechnol; 2019 Jun; 298():16-20. PubMed ID: 30959137
[TBL] [Abstract][Full Text] [Related]
4. RCD24, B7-H4 and PCNA expression and clinical significance in ovarian cancer.
Zheng C; Yang R
J BUON; 2019; 24(2):715-719. PubMed ID: 31128028
[TBL] [Abstract][Full Text] [Related]
5. CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis.
Burgos-Ojeda D; Wu R; McLean K; Chen YC; Talpaz M; Yoon E; Cho KR; Buckanovich RJ
Mol Cancer Ther; 2015 Jul; 14(7):1717-27. PubMed ID: 25969154
[TBL] [Abstract][Full Text] [Related]
6. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
[TBL] [Abstract][Full Text] [Related]
7. Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.
Zhu J; Nie S; Wu J; Lubman DM
J Proteome Res; 2013 Jun; 12(6):2791-804. PubMed ID: 23679566
[TBL] [Abstract][Full Text] [Related]
8. Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours.
Nagare RP; Sneha S; Sidhanth C; Roopa S; Murhekar K; Shirley S; Swaminathan R; Sridevi V; Ganesan TS
Cancer Biomark; 2020; 28(3):397-408. PubMed ID: 32224528
[TBL] [Abstract][Full Text] [Related]
9. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.
Durko L; Wlodarski W; Stasikowska-Kanicka O; Wagrowska-Danilewicz M; Danilewicz M; Hogendorf P; Strzelczyk J; Malecka-Panas E
Dis Markers; 2017; 2017():3276806. PubMed ID: 28659655
[TBL] [Abstract][Full Text] [Related]
10. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity.
Jaggupilli A; Elkord E
Clin Dev Immunol; 2012; 2012():708036. PubMed ID: 22693526
[TBL] [Abstract][Full Text] [Related]
11. Nicotine inhibits CD24 expression in Lewis lung carcinoma cells by upregulation of RAS expression.
Liu DH; An M; Bao BL; Ren F; Xia P
Int J Oncol; 2018 Aug; 53(2):815-822. PubMed ID: 29845249
[TBL] [Abstract][Full Text] [Related]
12. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
Chen C; Zhang L; Ruan Z
Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic value of CD24 expression in breast cancer: a meta-analysis.
Liu G; Liu GX; Fang Y; Cao ZY; Du HH; Fu J; Qian K
Int J Biol Markers; 2017 May; 32(2):e182-e189. PubMed ID: 28315505
[TBL] [Abstract][Full Text] [Related]
14. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
[TBL] [Abstract][Full Text] [Related]
15. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
16. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
17. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.
Klapdor R; Wang S; Morgan M; Dörk T; Hacker U; Hillemanns P; Büning H; Schambach A
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717444
[TBL] [Abstract][Full Text] [Related]
19. Novel insights into the function of CD24: A driving force in cancer.
Altevogt P; Sammar M; Hüser L; Kristiansen G
Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.
Tao Y; Li H; Huang R; Mo D; Zeng T; Fang M; Li M
Cell Physiol Biochem; 2018; 46(4):1716-1726. PubMed ID: 29730663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
